Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1. fázis

A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy

A legfontosabb adatok

Ki végzi
Bayer
Hol
Aurora (Egyesült Államok)A helyszín megnézéseMég 4 másik országban, 20 helyszínen
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
36 fő, tervezett
Kezdés
2025. márc. 12.
Várható befejezés
2027. jan. 17.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • BAY3389934
A regiszteradat frissítve
2026. november 10.

Ki vehet részt

Életkor
18 év – 85 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Participant must be ≥ 18 and ≤ 85 years of age at the time of signing the informed consent
  • Participants with diagnosed sepsis according to sepsis-3 criteria. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection
  • participants with suspected or documented origin of infection
  • Participants with coagulopathy defined by at least one of the following within 24 hours prior start of study intervention: INR ≥1.40, platelet count in the range of ≥ 30,000/mm3 to < 150,000/mm3 OR greater than 30% decrease in platelets in 24 hours without other known etiology. The platelet count after decrease should not be < 30,000/mm3
  • Participants must be receiving treatment in an ICU
  • Informed consent of capable participant or, in case of participant being incapable of giving informed consent, consent for study inclusion will be sought according to applicable laws and regulations

Ki nem vehet részt

  • Participants experienced major surgery or major trauma (intrathoracic, intra-abdominal, pelvic or femur) or surgery/trauma in any other area with potentially clinically significant consequences due to bleeding within 28 days before study drug administration
  • Participants experienced neurotrauma or neurosurgery (brain, spine) or orthopedic surgery in spine within 6 months before study drug administration
  • Clinically significant active bleeding; known bleeding disorder, history of major traumatic or non-traumatic bleeding (intracranial, retroperitoneal, intraocular) or clinically significant gastrointestinal bleeding within last 6 months
  • Participants with:; Uncontrolled malignancy requiring ongoing chemotherapy, radiation therapy, or immunotherapy within the past 6 months with the exception of: low-risk localized prostate cancer (Gleason score is equal to or less than 6 AND Prostate- Specific Antigen is below 10 ng/mL); or cervical carcinoma in situ; or ductal carcinoma in situ; or adequately treated non-metastatic squamous cell skin carcinoma; or adequately treated basal cell skin carcinoma. Patients with breast or prostate cancer receiving single endocrine (hormonal) therapy are eligible if all other cancer-directed treatments were completed more than 6 months prior to screening; Any hematological malignancy; Any active or prior malignancy involving the central nervous system (brain or spinal cord), including primary tumors or metastases
  • Chronic liver disease Child-Pugh Class C
  • Low platelets level or abnormal coagulation status due to any other reason than sepsis
  • Participants with indication for therapeutic dose of: anticoagulation (heparin, argatroban, vitamin K antagonists/warfarin, dabigatran, apixaban, rivaroxaban, edoxaban), oral antiplatelet agents (clopidogrel, ticagrelor, ticlopidine, prasugrel) except low dose (≤100mg) acetyl salicylic acid (ASA), digoxin, metformin
  • Pregnancy or breastfeeding

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 85 év között vagy?

Helyszínek itt: Egyesült Államok

Még 4 másik országban, 20 helyszínen

  • UC Health University of Colorado Hospital - Medical Intensive Care UnitAurora, Egyesült ÁllamokToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

Researchers are looking for a better way to treat people who have sepsis induced coagulopathy.

A teljes eredeti leírásKevesebb

Sepsis happens when bacteria and their toxins spread in the blood, causing an infection. To overcome the infection the body responds activating the immune system, sometimes this immune response is too active and causes uncontrolled blood clot formation, also called sepsis-induced coagulopathy. Sepsis coagulopathy damages blood vessels and organs and leads to low platelet levels in the body. In severe cases, it can even lead to death.

The main purpose of this first in patient study is to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis induced coagulopathy. For this study, researchers will enroll people receiving treatment for sepsis induced coagulopathy in a hospital intensive care unit (ICU).

For this, the researchers will collect the number of participants with medical problems during and after receiving BAY 3389934. These medical problems are also known as "adverse events". Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments.

Participants will be divided into 2 groups. The first group will receive the lowest starting dose of BAY3389934. The researcher will carefully monitor how the participant responds to the medication and may adjust the dose, either increasing or decreasing it based on the safety and the tolerability of the drug. If no serious side effects are reported from the first group, the second group will receive higher dose of BAY3389934.

Each participant will be in the study for around 28 days. During the study, the doctors and their study team will:

* Take blood and urine samples, * Do physical examinations, * Check vital signs such as body temperature, blood pressure and heart rate, * Examine heart health using electrocardiogram (ECG)

A vizsgálat 2 csoportja

  • Cohort 1 of BAY3389934A vizsgált kezelés

    Subjects will receive titrated dose of BAY3389934 as continuous infusion over up to 96 hours.

    Kezelés: BAY3389934

  • Cohort 2 of BAY3389934A vizsgált kezelés

    Subjects will receive titrated dose of BAY3389934 as continuous infusion over up to 96 hours.

    Kezelés: BAY3389934

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
First in Patient, Dose Escalation, Open Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion of BAY 3389934 to Patients With Sepsis Induced Coagulopathy
Kérdések a feltételekről
Forrás: NCT06854640: ki vehet részt
A regiszteradat frissítve
2026. november 10.